Skip to content

Electrosclerotherapy as a novel treatment option for capillary malformations: a pilot study

Electrosclerotherapy as a novel treatment option for capillary malformations: a pilot study - Electrosclerotherapy for capillary malformations

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45598
Enrollment
20
Registered
2017-08-16
Start date
2017-01-19
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capillary malformations port-wine stains

Interventions

All participants undergo one intervention session in which 3 homogeneous 1.5x1.5 cm parts of the capillary malformation are randomly allocated to [1] electrosclerotherapy, [2] bleomycin injection wi
bleomycin
capillary malformations
port-wine stains
vascular malformations

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Patients with *1 completely or partially hypertrophic capillary malformation not exclusively located in the skin of the face, the skin overlying joints or in mucosal tissue - Age * 18 years - Fitzpatrick skin type 1-3 without evident sun tan

Exclusion criteria

Exclusion criteria: - Pregnant or breastfeeding women - Women with childbearing potential not using contraception - Patients with chronic renal dysfunction of GFR

Design outcomes

Primary

MeasureTime frame
The study parameters are (change in) global assessment of color, thickness, nodularity, pliability, surface area and overall improvement by both the blinded patient and a blinded observer using a global assessment score and the POSAS instrument.

Secondary

MeasureTime frame
Number and type(s) of adverse events. (Change in) objective color measurement using colorimetry. (Change in) perfusion measured using optical imaging.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)